EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
N Rajea, X Leleub, A Lesokhinc, M Mohtyd, A Nookae, E Leipf, U Conteg, A Viqueirah, V Blunki, S Manierj
a Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States
b Centre Hospitalier Universitaire de Poitiers, Poitiers, France
c Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States
d Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France
e Winship Cancer Institute, Atlanta, United States
f Pfizer Inc, Cambridge, United States
g Pfizer Inc, New York, United States
j Lille University Hospital, Lille, France
Ver másRead
297
Timeswas read the article
118
Total PDF
179
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 May | 31 | 22 | 53 |
| 2024 April | 65 | 13 | 78 |
| 2024 March | 32 | 15 | 47 |
| 2024 February | 22 | 12 | 34 |
| 2024 January | 9 | 12 | 21 |
| 2023 December | 7 | 18 | 25 |
| 2023 November | 8 | 18 | 26 |
| 2023 October | 5 | 8 | 13 |
